Ketamine for Chronic Pain: How NMDA Antagonism Breaks the Pain Cycle

Ketamine for chronic pain works by blocking NMDA receptors that keep the nervous system in a state of central sensitization, and for chronic migraine its relief usually begins within hours of an infusion but often fades within days to weeks. CGRP inhibitors work the other way around: the American Headache Society (2021) advises waiting at least 3 months on a monthly CGRP antibody before judging it, because these drugs build a preventive effect that lasts as long as treatment continues.

Chronic pain is not just acute pain that refuses to go away. At a certain point, the nervous system itself changes. Neurons in the spinal cord and brain become hypersensitive, amplifying pain signals, creating pain from stimuli that should not hurt, and maintaining the pain experience long after the original injury has healed. This process, called central sensitization, is what turns a temporary injury into a long-term condition, and it sits underneath many forms of chronic pain.

Most pain medications work at the periphery (NSAIDs, local anesthetics) or dampen the brain’s perception of pain (opioids). Neither class does much to address central sensitization itself. Ketamine is different. By blocking NMDA receptors, it targets the very mechanism that drives the transition from acute to chronic pain, and it can, in some patients, effectively “reset” the pain processing system.

The sections below explain how that mechanism works, which pain conditions respond best, how ketamine compares with CGRP inhibitors for chronic migraine, what treatment protocols look like, and how pain-focused ketamine therapy differs from the depression protocols that get most of the attention. Clinicians and patients also call it ketamine infusion therapy, IV ketamine, low-dose ketamine or sub-anesthetic ketamine.

Central Sensitization: Why Chronic Pain Persists

To understand why ketamine works for chronic pain, you need to understand what is going wrong in the nervous system.

Under normal conditions, pain signals travel from an injury site through peripheral nerves to the dorsal horn of the spinal cord, where they are processed and relayed to the brain. This system has built-in modulation: the brain can turn the volume up or down on incoming pain signals depending on context.

In central sensitization, this modulation breaks down. Repeated or intense pain signaling causes neurons in the dorsal horn to become persistently hyperexcitable. NMDA (N-methyl-D-aspartate) receptors play a central role in this process. Under normal conditions, NMDA receptors on spinal cord neurons are blocked by a magnesium ion that prevents them from firing.

Sustained pain input removes this magnesium block, allowing NMDA receptors to activate. Once active, they trigger a cascade of intracellular changes (including calcium influx, activation of protein kinases, and gene expression changes) that make the neuron persistently more sensitive to input.

The clinical results of central sensitization include:

• Hyperalgesia: Painful stimuli feel more painful than they should.
• Allodynia: Normally non-painful stimuli (light touch, clothing against skin) are perceived as painful.
• Spontaneous pain: Pain that occurs without any external stimulus.
• Expanded pain fields: Pain that spreads beyond the area of original injury.

These are hallmark features of conditions like CRPS, fibromyalgia, neuropathic pain, and chronic migraine. Because NMDA receptors drive the process, blocking them with ketamine is a logical therapeutic strategy.

How Ketamine Interrupts the Pain Cycle

Ketamine is a non-competitive NMDA receptor antagonist, meaning it blocks the receptor’s ion channel regardless of how much glutamate is present. When administered at sub-anesthetic doses, ketamine:

1. Blocks NMDA receptors on dorsal horn neurons, directly reducing the excitability that drives central sensitization.
2. Reduces wind-up, the progressive increase in pain signaling that occurs with repeated stimulation of C-fibers (the nerve fibers that carry slow, burning pain).
3. Modulates glial cell activation. Microglia and astrocytes in the spinal cord become activated in chronic pain states and release pro-inflammatory mediators that further sensitize neurons. Ketamine appears to reduce this neuroinflammatory component.
4. Promotes neuroplasticity. Through the same BDNF and synaptogenesis mechanisms that underlie its antidepressant effects, ketamine may help the nervous system reorganize away from maladaptive pain processing patterns.
5. Has intrinsic anti-inflammatory effects that reduce peripheral and central inflammation, which contributes to pain maintenance in many chronic conditions.

The combination of these mechanisms is what sets ketamine apart from most analgesics. It does not just mask the pain signal; it addresses the neural changes that sustain chronic pain in the first place. The ketamine therapy treatment guide covers the drug itself, including its psychiatric uses and how infusions are delivered.

Evidence by Condition

The 2018 consensus guidelines on IV ketamine infusions for chronic pain, written by Cohen and colleagues for the American Society of Regional Anesthesia and Pain Medicine (ASRA), the American Academy of Pain Medicine (AAPM) and the American Society of Anesthesiologists (ASA), concluded that evidence supports ketamine for chronic pain but that the level of evidence varies by condition and dose range. The subsections below follow that pattern, from the strongest evidence to the thinnest.

Complex Regional Pain Syndrome (CRPS)

CRPS is arguably the condition with the strongest evidence for ketamine in chronic pain. It is also one of the most severe chronic pain conditions, characterized by burning pain, swelling, skin changes, and motor dysfunction, typically in an extremity following injury or surgery.

A 2009 randomized, double-blind, placebo-controlled trial by Sigtermans and colleagues found that a 4-day continuous IV ketamine infusion produced significant pain relief in CRPS patients lasting up to 12 weeks after treatment. A 2010 study by Schwartzman and colleagues used a 5-day inpatient ketamine infusion protocol and reported meaningful pain reduction with improvements sustained at 3-month follow-up. Multiple case series have documented similar results, with some patients experiencing pain relief lasting months after treatment.

The 2018 consensus guidelines on IV ketamine for chronic pain (Cohen et al., published in Regional Anesthesia & Pain Medicine) gave ketamine for CRPS a moderate-to-strong recommendation based on the available evidence. Ketamine sits alongside physical therapy, nerve blocks and spinal cord stimulation among the CRPS treatment options that pain specialists weigh.

Neuropathic Pain

Neuropathic pain (pain caused by damage or dysfunction of the nervous system itself) involves many of the same NMDA-dependent mechanisms as CRPS. Conditions in this category include diabetic neuropathy, post-herpetic neuralgia, spinal cord injury pain, and chemotherapy-induced peripheral neuropathy.

A 2019 systematic review in Pain Medicine found that IV ketamine produced short-term pain relief in neuropathic pain conditions, with effects typically lasting days to weeks after a single infusion. Repeated infusion protocols showed longer-lasting benefits, though the evidence is inconsistent across studies due to varying protocols and patient populations.

The consensus guidelines rate the evidence for neuropathic pain as moderate, noting that response varies significantly by the specific type of neuropathy. Ketamine is usually considered after gabapentinoids, antidepressants and topical agents, which are covered in more depth in our overview of neuropathic pain treatment.

Fibromyalgia

Fibromyalgia is a central sensitization syndrome by definition, making it a theoretically ideal target for ketamine therapy. A small but notable 2000 study by Graven-Nielsen and colleagues found that IV ketamine reduced muscle pain and referred pain in fibromyalgia patients, with results suggesting that NMDA receptor activation plays a significant role in maintaining fibromyalgia symptoms.

A 2016 randomized crossover trial found that a single ketamine infusion (0.5 mg/kg over 40 minutes, the standard depression dose) produced modest but significant pain reduction in fibromyalgia patients compared to saline placebo. The effects were short-lived (hours to days), suggesting that multi-day or repeated protocols may be needed for more durable results.

The evidence for fibromyalgia is promising but limited. Most studies are small, and there is no consensus on optimal dosing or protocol duration. Ketamine is best considered as an option for fibromyalgia patients who have not responded to standard fibromyalgia treatments (duloxetine, pregabalin, exercise therapy).

Chronic Migraine

Central sensitization is increasingly recognized as a driver of chronic migraine and medication-overuse headache. Case series and retrospective studies have reported that IV ketamine infusions can break refractory migraine cycles, particularly status migrainosus (migraine lasting longer than 72 hours) and chronic daily headache that has not responded to triptans, CGRP inhibitors, or nerve blocks.

A 2017 retrospective study at Thomas Jefferson University found that ketamine infusions reduced pain severity in 75% of patients admitted for refractory headache, with a mean reduction from 7.1 to 3.8 on a 10-point scale. These results come from uncontrolled studies in an inpatient setting, and randomized trial data for migraine-specific applications is lacking. The 2018 consensus guidelines rated the support for ketamine in headache as weaker than for CRPS.

Ketamine vs. CGRP Inhibitors for Chronic Migraine: How the Timelines Compare

Ketamine and CGRP inhibitors answer different questions on different clocks. A ketamine infusion is a rescue or bridge treatment that can lower migraine pain within hours, during the infusion itself, but relief after a single course often fades within days to weeks. CGRP inhibitors are preventive medicines that reduce the number of monthly migraine days over weeks to months, and they keep working for as long as a patient stays on them.

CGRP (calcitonin gene-related peptide) is a signaling molecule released by trigeminal nerves during a migraine attack. The CGRP monoclonal antibodies erenumab, fremanezumab, galcanezumab and eptinezumab block CGRP or its receptor, and the FDA began approving them for migraine prevention in 2018. The small-molecule gepants (ubrogepant, rimegepant, atogepant and zavegepant) block the CGRP receptor too, some for acute attacks and some for prevention.

How fast does ketamine relieve migraine pain?

Ketamine lowers pain while it is being infused, so patients in inpatient protocols usually notice a change within the first hours or days of the stay. The Jefferson data above measured pain across a hospital admission, and a retrospective design cannot show how long relief lasts afterward. Many headache specialists treat a ketamine course as a way to break a cycle, then lean on a preventive plan to keep the gains.

How fast do CGRP inhibitors work?

CGRP monoclonal antibodies are slower to show their full effect. Some patients have fewer migraine days within the first month, but the American Headache Society consensus statement update (Ailani, Burch and Robbins, 2021) recommends judging benefit after at least 3 months for monthly injections and at least 6 months for quarterly dosing. It also notes data suggesting continued improvement beyond 3 months. Our overview of migraine medication covers triptans, gepants and older preventives.

Can ketamine and CGRP inhibitors be used together?

Many patients in ketamine migraine studies had already tried CGRP inhibitors or other preventives, so in practice the two are often layered rather than chosen between. No randomized trial has tested the combination, so the evidence for pairing them is thin. A neurologist or headache specialist usually decides the order, and the migraine treatment guide describes where each option fits for people with chronic migraine.

Pain Protocols vs. Depression Protocols

This is a crucial distinction. The ketamine doses and protocols used for chronic pain are substantially different from those used for depression. Pain protocols run longer, use more drug in total and need closer monitoring.

Parameter	Depression Protocol	Pain Protocol
Typical dose	0.5 mg/kg over 40 minutes	0.5 to 1.0+ mg/kg/hr, sometimes higher for CRPS
Infusion duration	40 minutes	4 hours to multiple days (continuous)
Number of sessions	6 over 2 to 3 weeks	1 to 5 day infusions, repeated as needed
Setting	Outpatient clinic	Often inpatient or monitored outpatient for multi-day protocols
Total ketamine dose	35 to 50 mg per session (for 70 kg patient)	Can exceed several hundred mg over multi-day protocols
Monitoring level	Vital signs, pulse oximetry	Continuous cardiac monitoring for higher doses

The higher doses and longer durations used in pain protocols carry greater risks, including more pronounced dissociation, higher risk of cardiovascular effects, and greater potential for bladder irritation with repeated treatments. These protocols are typically administered by anesthesiologists or pain medicine specialists, often in hospital settings.

Duration of Relief

One of the most common questions patients ask is how long the pain relief will last. The honest answer is that it varies enormously:

• After a single infusion (depression dose): Hours to days for most pain conditions.
• After a multi-day infusion (CRPS protocol): Weeks to months. Some CRPS patients report 3 to 6 months of meaningful relief after a 4 to 5 day infusion course.
• After a series of outpatient infusions: Typically 2 to 8 weeks, depending on the condition and protocol.
• With maintenance infusions: Many pain patients require periodic “booster” infusions (monthly to quarterly) to sustain benefits.

Factors that influence duration of relief include the underlying condition, how long you have had chronic pain (longer duration generally means shorter relief), whether you are using other pain management strategies concurrently (physical therapy, medications, nerve blocks), and individual variation in how your nervous system responds to NMDA blockade.

For chronic migraine specifically, this pattern is the main difference from CGRP inhibitors. Ketamine relief tends to arrive fast and fade, while a CGRP antibody builds slowly and holds for as long as it is taken.

Safety Considerations for Pain Patients

The side effect profile for pain-dose ketamine is similar to but amplified compared to depression-dose treatment. Key considerations:

• Dissociation: More pronounced at higher doses. Most patients find it manageable, but some find it distressing. Pre-treatment with a benzodiazepine (midazolam or lorazepam) can reduce this effect.
• Cardiovascular: Higher doses produce more significant increases in blood pressure and heart rate. Continuous monitoring is essential.
• Bladder: The risk of ketamine-induced cystitis is theoretically higher with the larger cumulative doses used in pain protocols, though it remains rare in clinical settings. Patients on long-term maintenance should be monitored for urinary symptoms.
• Cognitive: Some patients report transient memory difficulties and “brain fog” for 24 to 48 hours after higher-dose infusions. This typically resolves completely.
• Nausea: More common at higher doses. Pre-treatment with ondansetron helps.

Who should avoid ketamine for pain?

Clinicians generally avoid ketamine, or use it only with extra caution, in people with poorly controlled high blood pressure or heart disease, a history of psychosis, severe liver disease, raised pressure inside the skull or eye, active substance misuse, or pregnancy. A careful intake covers each of these before a first infusion, along with current medications and any past reaction to anesthesia.

Ketamine is also a Schedule III controlled substance under the Drug Enforcement Administration (DEA), so repeated use is monitored for misuse. Questions about the dissociative experience itself are covered in our post on whether ketamine therapy gets you high.

Is Ketamine FDA Approved for Chronic Pain? Regulation, Cost and Insurance

Ketamine has been FDA approved as an anesthetic since 1970, but it is not FDA approved for chronic pain, CRPS, fibromyalgia or migraine. Doctors use it for these conditions off label, which is legal and common in pain medicine. Esketamine, the S-enantiomer of ketamine given as a nasal spray, is FDA approved only for treatment-resistant depression and depressive symptoms with suicidal thoughts, not for pain.

Because pain use is off label, most outpatient ketamine clinics are cash pay. Hospital-based inpatient protocols run by anesthesiology or pain medicine departments are sometimes billed to insurance, and coverage varies by plan and diagnosis. Ask for a written quote that lists the infusion, monitoring and any medications before you commit. Our guides to ketamine therapy cost and insurance coverage for ketamine therapy explain what drives the bill, and esketamine versus IV ketamine covers the differences between the two drugs.

When to Consider Ketamine for Pain

Ketamine for chronic pain is generally considered a second- or third-line option. It makes the most sense in these scenarios:

• You have a diagnosed central sensitization condition (CRPS, neuropathic pain, fibromyalgia) that has not responded adequately to first-line treatments.
• You are on high-dose opioids and your provider wants to reduce opioid dependence (ketamine can provide pain relief while facilitating opioid tapering).
• You have chronic pain with co-existing depression, allowing one treatment to address both conditions.
• You are in a pain crisis (such as a CRPS flare or status migrainosus) that is not responding to standard interventions.

Start the conversation with a pain medicine specialist or anesthesiologist who has experience with ketamine protocols for pain. Your primary care doctor or current pain management provider can help coordinate a referral. For a broader overview of ketamine therapy and its applications, see our full guide. If you are dealing with chronic pain more broadly, our chronic pain management guide covers the full range of available treatments.

How to Find a Ketamine Clinic for Chronic Pain

Ketamine for chronic pain is offered by hospital pain programs, anesthesiology practices and independent ketamine clinics, and their protocols differ more than their websites suggest. The national directory of ketamine therapy clinics lists providers by state and city, and each profile shows which treatments a clinic offers. These questions help you sort a pain-capable clinic from a depression-only one:

1. Does the clinic run pain protocols, including multi-hour or multi-day infusions, or only the 40-minute depression infusion?
2. Who supervises the infusion: an anesthesiologist, a pain medicine physician, or a nurse under remote supervision?
3. What monitoring is used during and after the infusion, including continuous cardiac monitoring at higher doses?
4. Will the clinic coordinate with your pain specialist, neurologist or headache specialist and send records after each course?
5. How does the clinic decide whether to offer booster infusions, and when would it stop treatment that is not helping?

Regenerated.com is free for patients, and listing order is not paid ranking. Featured slots are labeled and capped, and Verified means credential checks, not spend. Inclusion in the directory is not an endorsement, and our guide to Featured, Verified and organic listings explains each label. If migraine is the main problem, the migraine treatment clinic list includes headache-focused providers as well.

The Bottom Line

Ketamine stands apart from conventional pain medications because it targets the mechanism that perpetuates chronic pain rather than simply dampening the pain signal. For patients with CRPS, neuropathic pain, fibromyalgia, and refractory migraine, it represents a genuine option when standard treatments have fallen short. The evidence is strongest for CRPS and neuropathic pain, with promising but less robust data for fibromyalgia and migraine.

For chronic migraine, ketamine works on a short clock and CGRP inhibitors on a long one. Ketamine can bring relief within hours that often fades in days to weeks, while CGRP antibodies need at least 3 months to judge and then work for as long as they are continued.

Pain-focused ketamine therapy requires higher doses, longer infusions, and more intensive monitoring than the depression protocols that dominate public awareness. Make sure your provider has the training and infrastructure to deliver these protocols safely. And remember that ketamine works best not as a standalone solution but as one tool within a broader pain management strategy that includes physical rehabilitation, psychological support, and appropriate pharmacotherapy.

Frequently asked questions

How does ketamine’s pain relief timeline compare with CGRP inhibitors for chronic migraine?

Ketamine works faster but usually for a shorter time. An IV ketamine infusion can lower migraine pain within hours, and relief after a single course often fades within days to weeks. CGRP monoclonal antibodies are preventive drugs that reduce monthly migraine days gradually, and the American Headache Society (2021) advises judging them after at least 3 months of monthly dosing. Their benefit lasts as long as treatment continues, while ketamine often needs booster infusions.

Is ketamine therapy for chronic pain FDA approved?

Ketamine is FDA approved as an anesthetic, not for chronic pain, so pain clinics use it off label. Off-label prescribing is legal and common, and the 2018 consensus guidelines from ASRA, AAPM and ASA support ketamine for some pain conditions, with the strongest evidence for CRPS. Esketamine nasal spray is FDA approved only for treatment-resistant depression. Because pain use is off label, most outpatient ketamine clinics are cash pay.

Which chronic pain conditions respond best to ketamine?

Complex regional pain syndrome (CRPS) has the strongest evidence, including a 2009 randomized trial by Sigtermans and colleagues showing relief lasting up to 12 weeks after a 4-day infusion. Neuropathic pain has moderate evidence, with relief often lasting days to weeks after one infusion. Fibromyalgia and refractory migraine have promising but limited data, mostly from small or uncontrolled studies, so responses in those conditions are less predictable.

How many ketamine infusions do you need for chronic pain?

The number depends on the protocol and the condition, and there is no single standard. Pain programs often use a continuous infusion over 1 to 5 days, or a series of multi-hour outpatient infusions, followed by booster infusions monthly to quarterly if relief holds. Depression protocols typically use 6 short infusions over 2 to 3 weeks, which is often too little for pain conditions such as CRPS.

Who gives ketamine infusions for chronic pain?

Anesthesiologists and pain medicine physicians run most ketamine pain protocols, often in hospital pain programs or monitored outpatient clinics. Neurologists and headache specialists refer patients with refractory migraine, and psychiatrists often oversee ketamine for depression. Ask who supervises each infusion and what cardiac monitoring is used, because pain doses are higher and longer than the 40-minute depression infusion many independent clinics offer.

Related Reading

• Ketamine Therapy: The Complete Guide
• Chronic Pain Management Without Opioids
• Ketamine for Depression
• Biofeedback for Chronic Pain